{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:35:10Z","timestamp":1793198110480,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.biopha.2022.114081","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T19:29:33Z","timestamp":1670268573000},"page":"114081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The treatment of inflammatory bowel disease with monoclonal antibodies in Asia"],"prefix":"10.1016","volume":"157","author":[{"given":"Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Arenbaoligao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cgh.2019.11.054","article-title":"Diet in treatment of inflammatory bowel diseases","volume":"19","author":"Sasson","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12325-019-01151-w","article-title":"Fatigue in inflammatory bowel diseases: etiologies and management","volume":"37","author":"Nocerino","year":"2020","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"10114","key":"10.1016\/j.biopha.2022.114081_bib4","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.114081_bib5","doi-asserted-by":"crossref","unstructured":"Cancer multidrug resistance. Nat Biotechnol, 2000. 18 Suppl: p. It18\u201320.","DOI":"10.1038\/80051"},{"issue":"7","key":"10.1016\/j.biopha.2022.114081_bib6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00535-009-0057-3","article-title":"Prevalence of ulcerative colitis and Crohn's disease in Japan","volume":"44","author":"Asakura","year":"2009","journal-title":"J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.biopha.2022.114081_bib7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1046\/j.1440-1746.2000.02212.x","article-title":"Racial differences in the prevalence of ulcerative colitis and Crohn's disease in Singapore","volume":"15","author":"Lee","year":"2000","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2022.114081_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3748\/wjg.v10.i9.1341","article-title":"Epidemiology and outcome of Crohn's disease in a teaching hospital in Riyadh","volume":"10","author":"Al-Ghamdi","year":"2004","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.biopha.2022.114081_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3349\/ymj.2021.62.2.99","article-title":"Incidence and prevalence of inflammatory bowel disease across Asia","volume":"62","author":"Park","year":"2021","journal-title":"Yonsei Med J."},{"key":"10.1016\/j.biopha.2022.114081_bib10","article-title":"Exploring links between industrialization, urbanization, and chinese inflammatory bowel disease","volume":"8","author":"Cui","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.biopha.2022.114081_bib11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/17512433.2017.1318062","article-title":"Optimizing pharmacologic management of inflammatory bowel disease","volume":"10","author":"Chang","year":"2017","journal-title":"Expert Rev. Clin. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2022.114081_bib12","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am. J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.biopha.2022.114081_bib13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/jgh.14648","article-title":"Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia","volume":"34","author":"Ooi","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.biopha.2022.114081_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2468-1253(21)00062-5","article-title":"Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial","volume":"6","author":"Kobayashi","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10080","key":"10.1016\/j.biopha.2022.114081_bib16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2022.114081_bib17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s10620-019-05867-1","article-title":"Biologic use patterns and predictors for non-persistence and switching of biologics in patients with inflammatory bowel disease: a nationwide population-based study","volume":"65","author":"Jung","year":"2020","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jgh.14019","article-title":"Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment","volume":"33","author":"Park","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jgh.14018","article-title":"Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management","volume":"33","author":"Park","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jgh.14872","article-title":"The epidemiology of inflammatory bowel disease: East meets west","volume":"35","author":"Mak","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jgh.12958","article-title":"Asia-Pacific consensus statements on Crohn's disease. Part 2: Management","volume":"31","author":"Ooi","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.biopha.2022.114081_bib22","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/14712598.2019.1652267","article-title":"Inflammatory cytokines: from discoveries to therapies in IBD","volume":"19","author":"Marafini","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2022.114081_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","author":"Neurath","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/19490976.2015.1121364","article-title":"The Intersection of TNF, IBD and the Microbiome","volume":"7","author":"Jones-Hall","year":"2016","journal-title":"Gut Microbes"},{"issue":"6","key":"10.1016\/j.biopha.2022.114081_bib25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/gutjnl-2019-318264","article-title":"Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling","volume":"69","author":"Koelink","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.biopha.2022.114081_bib26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00054725-199811000-00014","article-title":"Infliximab approved for use in Crohn's disease: a report on the FDA GI advisory committee conference","volume":"4","author":"Kornbluth","year":"1998","journal-title":"Inflamm. Bowel Dis."},{"issue":"9","key":"10.1016\/j.biopha.2022.114081_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: practical insights","volume":"12","author":"Danese","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2022.114081_bib28","first-page":"1819","article-title":"FDA approves Cimzia to treat Crohn's disease","volume":"134","author":"Lang","year":"2008","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.biopha.2022.114081_bib29","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2146\/news090045","article-title":"Once-a-month injection approved to treat three types of arthritis","volume":"66","author":"Thompson","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.biopha.2022.114081_bib30","first-page":"17","article-title":"Role of adalimumab, a novel TNF antagonist in advancing rheumatoid arthritis control","volume":"39","author":"Emery","year":"2003"},{"issue":"4","key":"10.1016\/j.biopha.2022.114081_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2217\/imt.10.34","article-title":"Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies","volume":"2","author":"Hutas","year":"2010","journal-title":"Immunotherapy"},{"issue":"suppl_2","key":"10.1016\/j.biopha.2022.114081_bib32","doi-asserted-by":"crossref","first-page":"S653","DOI":"10.1093\/ecco-jcc\/jjy060","article-title":"Gut-selective integrin-targeted therapies for inflammatory bowel disease","volume":"12","author":"Lamb","year":"2018","journal-title":"J. Crohns Colitis"},{"issue":"17","key":"10.1016\/j.biopha.2022.114081_bib33","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","article-title":"Anti-integrin therapy for inflammatory bowel disease","volume":"24","author":"Park","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2022.114081_bib34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/2040622316653306","article-title":"Ustekinumab in Crohn's disease: evidence to date and place in therapy","volume":"7","author":"Engel","year":"2016","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmgh.2020.07.005","article-title":"Ustekinumab inhibits T follicular helper cell differentiation in patients With Crohn's Disease","volume":"11","author":"Globig","year":"2021","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2022.114081_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/1744666X.2014.878649","article-title":"Ustekinumab for the treatment of psoriatic arthritis","volume":"10","author":"Wofford","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/13696998.2019.1642900","article-title":"Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan","volume":"23","author":"Ueno","year":"2020","journal-title":"J. Med Econ."},{"issue":"5","key":"10.1016\/j.biopha.2022.114081_bib38","first-page":"460","article-title":"The role of ABO blood groups in Crohn's disease and in monitoring response to infliximab treatment","volume":"14","author":"Yu","year":"2016","journal-title":"Blood Transfus."},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000496453","article-title":"Adalimumab dose-escalation therapy is effective in refractory Crohn's disease patients with loss of response to adalimumab, especially in cases without previous infliximab treatment","volume":"13","author":"Suzuki","year":"2019","journal-title":"Case Rep. Gastroenterol."},{"issue":"10","key":"10.1016\/j.biopha.2022.114081_bib40","article-title":"Practical strategy for optimizing the timing of anti-tumor necrosis factor-\u03b1 therapy in Crohn disease: a nationwide population-based study","volume":"99","author":"Kwak","year":"2020","journal-title":"Med. (Baltim. )"},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5217\/ir.2019.09160","article-title":"Efficacy and safety of vedolizumab in Crohn's disease in patients from Asian countries in the GEMINI 2 study","volume":"19","author":"Banerjee","year":"2021","journal-title":"Intest Res"},{"issue":"7","key":"10.1016\/j.biopha.2022.114081_bib42","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MCG.0000000000000319","article-title":"Low-dose infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis","volume":"49","author":"Jiang","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3349\/ymj.2020.61.1.48","article-title":"Comparison of real-world outcomes of infliximab versus adalimumab in biologic-Na\u00efve Korean patients with ulcerative colitis: a population-based study","volume":"61","author":"Han","year":"2020","journal-title":"Yonsei Med J."},{"issue":"32","key":"10.1016\/j.biopha.2022.114081_bib44","article-title":"Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy","volume":"96","author":"Mizoshita","year":"2017","journal-title":"Med. (Baltim. )"},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5217\/ir.2019.09159","article-title":"Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study","volume":"19","author":"Ooi","year":"2021","journal-title":"Intest Res"},{"key":"10.1016\/j.biopha.2022.114081_bib46","first-page":"1","article-title":"Week 2 symptomatic response with vedolizumab as a predictive factor in Japanese Anti-TNF\u03b1-naive patients with ulcerative colitis: a post hoc analysis of a randomized, placebo-controlled phase 3 Trial","author":"Nagahori","year":"2021","journal-title":"Digestion"},{"issue":"4","key":"10.1016\/j.biopha.2022.114081_bib47","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/gutjnl-2020-322129","article-title":"Emerging treatment options for extraintestinal manifestations in IBD","volume":"70","author":"Greuter","year":"2021","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/ecco-jcc\/jjx158","article-title":"Expression Patterns of TNF\u03b1, MAdCAM1, and STAT3 in intestinal and skin manifestations of inflammatory bowel disease","volume":"12","author":"Vavricka","year":"2018","journal-title":"J. Crohns Colitis"},{"issue":"10","key":"10.1016\/j.biopha.2022.114081_bib49","first-page":"19184","article-title":"Pyoderma gangrenosum of articulations carpi associated with ulcerative colitis: one case report","volume":"8","author":"Meng","year":"2015","journal-title":"Int J. Clin. Exp. Med"},{"issue":"4","key":"10.1016\/j.biopha.2022.114081_bib50","first-page":"3997","article-title":"Osteoporosis as an initial manifestation in a patient with Crohn's disease: A case report","volume":"15","author":"Wei","year":"2018","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.biopha.2022.114081_bib51","first-page":"69","article-title":"Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn's disease","volume":"12","author":"Matsumoto","year":"2018","journal-title":"Biologics"},{"key":"10.1016\/j.biopha.2022.114081_bib52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/OARRR.S263259","article-title":"Efficacy of ustekinumab against spondyloarthritis associated with Crohn's Disease: a case report and review of the literature","volume":"12","author":"Matsumoto","year":"2020","journal-title":"Open Access Rheuma"},{"issue":"46","key":"10.1016\/j.biopha.2022.114081_bib53","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.3748\/wjg.v26.i46.7425","article-title":"Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report","volume":"26","author":"Huang","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"30","key":"10.1016\/j.biopha.2022.114081_bib54","article-title":"Ulcerative colitis with acute pleurisy: A case report and review of the literature","volume":"96","author":"Lu","year":"2017","journal-title":"Med. (Baltim. )"},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4166\/kjg.2018.72.3.141","article-title":"Pulmonary extraintestinal manifestation of Crohn's disease treated successfully with adalimumab","volume":"72","author":"Shin","year":"2018","journal-title":"Korean J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib56","article-title":"Crohn's disease with atypical extra-intestinal manifestations developing under treatment with vedolizumab","volume":"8","author":"Abu Shtaya","year":"2021","journal-title":"Eur. J. Case Rep. Intern Med"},{"issue":"5","key":"10.1016\/j.biopha.2022.114081_bib57","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jca.21821","article-title":"Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis","volume":"35","author":"Shibuya","year":"2020","journal-title":"J. Clin. Apher."},{"issue":"8","key":"10.1016\/j.biopha.2022.114081_bib58","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/00365521.2017.1323229","article-title":"Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea","volume":"52","author":"Seo","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.biopha.2022.114081_bib59","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/jgh.14624","article-title":"Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics","volume":"34","author":"Inokuchi","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.biopha.2022.114081_bib60","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s12325-016-0406-6","article-title":"A retrospective claims database study on drug utilization in japanese patients with Crohn's disease treated with adalimumab or infliximab","volume":"33","author":"Yokoyama","year":"2016","journal-title":"Adv. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2022.114081_bib61","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1007\/s10620-017-4715-7","article-title":"Long-Term Outcomes Of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-based Cohort Study From Korea","volume":"62","author":"Seo","year":"2017","journal-title":"Dig. Dis. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2022.114081_bib62","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1007\/s10620-016-4105-6","article-title":"Long-term outcomes of infliximab treatment in 582 Korean patients with Crohn's Disease: A Hospital-based Cohort Study","volume":"61","author":"Park","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2022.114081_bib63","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/jgh.13612","article-title":"Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease","volume":"32","author":"Cheon","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib64","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1128\/CVI.00401-07","article-title":"Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients","volume":"15","author":"Newton","year":"2008","journal-title":"Clin. Vaccin. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib65","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1756-185X.12530","article-title":"Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden","volume":"18","author":"Jung","year":"2015","journal-title":"Int J. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.114081_bib66","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820938960","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial","volume":"13","author":"Chen","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib67","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-019-01647-w","article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses","volume":"55","author":"Watanabe","year":"2020","journal-title":"J. Gastroenterol."},{"issue":"24","key":"10.1016\/j.biopha.2022.114081_bib68","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.2169\/internalmedicine.3054-19","article-title":"Bacteriologically determined de novo tuberculosis during tumor necrosis factor-\u03b1 inhibitor therapy","volume":"58","author":"Takahashi","year":"2019","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.biopha.2022.114081_bib69","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/ecco-jcc\/jjw060","article-title":"Safety of adalimumab and predictors of adverse events in 1693 Japanese Patients with Crohn's Disease","volume":"10","author":"Ogata","year":"2016","journal-title":"J. Crohns Colitis"},{"issue":"12","key":"10.1016\/j.biopha.2022.114081_bib70","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1046\/j.1440-1746.2000.0150121356.x","article-title":"Chronic hepatitis B virus infection in Asian countries","volume":"15","author":"Merican","year":"2000","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2022.114081_bib71","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/apt.16880","article-title":"Meta-analysis: hepatitis B vaccination in inflammatory bowel disease","volume":"55","author":"Singh","year":"2022","journal-title":"Aliment Pharm. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2022.114081_bib72","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jbspin.2014.01.015","article-title":"Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation","volume":"81","author":"Lunel-Fabiani","year":"2014","journal-title":"Jt. Bone Spine"},{"issue":"2","key":"10.1016\/j.biopha.2022.114081_bib73","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ibd\/izx001","article-title":"Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy","volume":"24","author":"Pratt","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.biopha.2022.114081_bib74","article-title":"Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease","volume":"2013","author":"Miyake","year":"2013","journal-title":"Case Rep. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2022.114081_bib75","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5217\/ir.2017.15.4.475","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies","volume":"15","author":"Hibi","year":"2017","journal-title":"Intest Res"},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jgh.15128","article-title":"Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan","volume":"36","author":"Takeuchi","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.biopha.2022.114081_bib77","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3345\/kjp.2014.57.11.465","article-title":"Current issues of pediatric inflammatory bowel disease in Korea","volume":"57","author":"Oh","year":"2014","journal-title":"Korean J. Pedia"},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib78","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/jgh.13498","article-title":"Treatment with infliximab for pediatric Crohn's disease: nationwide survey of Japan","volume":"32","author":"Hosoi","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2022.114081_bib79","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/jgh.14836","article-title":"Infliximab for very early-onset inflammatory bowel disease: a tertiary center experience in Japan","volume":"35","author":"Takeuchi","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2022.114081_bib80","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/MPG.0000000000002832","article-title":"Therapeutic drug monitoring-guided high-dose infliximab for infantile-onset inflammatory Bowel Disease: a case series","volume":"71","author":"Assa","year":"2020","journal-title":"J. Pedia Gastroenterol. Nutr."},{"issue":"12","key":"10.1016\/j.biopha.2022.114081_bib81","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1097\/MIB.0000000000001269","article-title":"Phenotype and management of infantile-onset inflammatory bowel disease: experience from a tertiary care center in China","volume":"23","author":"Ye","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"issue":"12","key":"10.1016\/j.biopha.2022.114081_bib82","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ejmg.2017.08.016","article-title":"Very early onset inflammatory bowel disease: Investigation of the IL-10 signaling pathway in Iranian children","volume":"60","author":"Nemati","year":"2017","journal-title":"Eur. J. Med Genet"},{"issue":"4","key":"10.1016\/j.biopha.2022.114081_bib83","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/ibd\/izy289","article-title":"Phenotypic characterization of very early-onset inflammatory bowel disease with interleukin-10 signaling deficiency: based on a large cohort study","volume":"25","author":"Zheng","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.biopha.2022.114081_bib84","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12876-016-0424-5","article-title":"Novel exonic mutation inducing aberrant splicing in the IL10RA gene and resulting in infantile-onset inflammatory bowel disease: a case report","volume":"16","author":"Yanagi","year":"2016","journal-title":"BMC Gastroenterol."},{"issue":"2","key":"10.1016\/j.biopha.2022.114081_bib85","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ajg.2009.562","article-title":"Ulcerative colitis and pregnancy outcomes in an Asian population","volume":"105","author":"Lin","year":"2010","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib86","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijgo.2005.06.003","article-title":"Inflammatory bowel disease and preterm delivery","volume":"90","author":"Elbaz","year":"2005","journal-title":"Int J. Gynaecol. Obstet."},{"issue":"8","key":"10.1016\/j.biopha.2022.114081_bib87","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ibd\/izy081","article-title":"Pregnancy-onset inflammatory bowel disease: a subtle diagnosis","volume":"24","author":"Koslowsky","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"issue":"9","key":"10.1016\/j.biopha.2022.114081_bib88","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/apt.15654","article-title":"Pregnancy outcomes in women with inflammatory bowel disease: a 10-year nationwide population-based cohort study","volume":"51","author":"Lee","year":"2020","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.114081_bib89","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1741-7015-11-174","article-title":"Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review","volume":"11","author":"Nielsen","year":"2013","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib90","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-tnfalpha drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY Study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.biopha.2022.114081_bib91","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5217\/ir.2016.14.2.139","article-title":"Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and\/or thiopurine therapy: a multicenter study from Japan","volume":"14","author":"Komoto","year":"2016","journal-title":"Intest Res"},{"issue":"2","key":"10.1016\/j.biopha.2022.114081_bib92","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000493462","article-title":"Pregnancy outcomes of patients exposed to adalimumab in Japan","volume":"37","author":"Kawai","year":"2019","journal-title":"Dig. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2022.114081_bib93","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2169\/internalmedicine.52.9466","article-title":"Maintenance of the remission stage of Crohn's disease with adalimumab therapy during pregnancy","volume":"52","author":"Mizoshita","year":"2013","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib94","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5217\/ir.2016.14.3.218","article-title":"Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries","volume":"14","author":"Wei","year":"2016","journal-title":"Intest Res"},{"key":"10.1016\/j.biopha.2022.114081_bib95","doi-asserted-by":"crossref","first-page":"3190548","DOI":"10.1155\/2018\/3190548","article-title":"The continental divide: anti-TNF Use in pediatric IBD Is different in North America compared to other parts of the world","volume":"2018","author":"Church","year":"2018","journal-title":"Can. J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2022.114081_bib96","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00054725-200309000-00001","article-title":"Defining complex contributions of NOD2\/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes","volume":"9","author":"Brant","year":"2003","journal-title":"Inflamm. Bowel Dis."},{"issue":"9","key":"10.1016\/j.biopha.2022.114081_bib97","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat. Genet"},{"issue":"6","key":"10.1016\/j.biopha.2022.114081_bib98","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/ibd.21845","article-title":"Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis","volume":"18","author":"Ng","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"issue":"5804","key":"10.1016\/j.biopha.2022.114081_bib99","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2022.114081_bib100","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/gutjnl-2012-303557","article-title":"Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease","volume":"63","author":"Guti\u00e9rrez","year":"2014","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biopha.2022.114081_bib101","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12967-017-1355-9","article-title":"Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease","volume":"15","author":"Nuij","year":"2017","journal-title":"J. Transl. Med"},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib102","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10067-020-05248-4","article-title":"Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data","volume":"40","author":"Lau","year":"2021","journal-title":"Clin. Rheuma"},{"issue":"2","key":"10.1016\/j.biopha.2022.114081_bib103","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/apt.13851","article-title":"Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea","volume":"45","author":"Hong","year":"2017","journal-title":"Aliment Pharm. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2022.114081_bib104","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5009\/gnl210081","article-title":"Clinical course of hepatitis B Viral infection in patients undergoing anti-tumor necrosis factor \u03b1 therapy for inflammatory bowel disease","volume":"16","author":"Lee","year":"2022","journal-title":"Gut Liver"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:13:17Z","timestamp":1778242397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222014706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":104,"alternative-id":["S0753332222014706"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114081","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The treatment of inflammatory bowel disease with monoclonal antibodies in Asia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114081"}}